Precision and Future Medicine (Mar 2017)

HER2, estrogen receptor-negative metastatic hidradenocarcinoma: identification of TP53 mutation in both primary and cell-free DNA

  • Siho Kim,
  • Jinhyun Cho,
  • Won Park,
  • Sang-Hee Choi,
  • Woongyang Park,
  • Kee-Taek Jang,
  • Jeeyun Lee

DOI
https://doi.org/10.23838/pfm.2017.00108
Journal volume & issue
Vol. 1, no. 1
pp. 52 – 57

Abstract

Read online

Hidradenocarcinoma is an extremely rare cutaneous skin carcinoma which arise from the sweat gland. There are several report about potential targets in this rare disease including estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). A 53-year-old man who presented with a slowly growing mass on the left thumb which was pathologically confirmed of HER2 negative, ER negative hidradenocarcinoma. At the time of presentation, the patient had metastatic lesions to lung and axillary lymph nodes. The patient received several lines of palliative chemotherapy and radiotherapy, but died of the disease progression. We identified TP53 G245S mutation in both primary tumor specimen and cell-free based targeted sequencing. Herein, we report on a very rare case of metastatic hidradenocarcinoma with TP53 G245S mutation but no other treatable targets from clinical sequencing, which pursued an aggressive clinical course.

Keywords